Invivyd
NASDAQ: IVVD5 known investors
Find your way into Invivyd
78 people in our graph share verified history with the Invivyd team — schools, employers, funds. One of them is your warm intro.
Erez Kalirunlockedknows Marc Elia · together at Tiger Management (overlapped)
×4knows the team · via Carleton College
×5knows the team · via Tiger Management
knows the team · via Bridger Capital LLC
knows the team · via Chiron Corporation
Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications. It uses a proprietary integrated technology platform to design antibodies that are more potent and resistant to viral evolution.
Founders & leadership
Investors · 5
Competitors · 3
by search overlap
IQVIA36 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld28 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha24 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Invivyd for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Invivyd says COVID antibody trial data is planned for late Q3stocktitan.net · Aug 2026
Invivyd posts larger loss and flags going-concern risk | IVVD Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Invivyd do?
- Invivyd develops monoclonal antibody medicines for the prevention and treatment of serious viral infectious diseases, starting with COVID-19 and other high-need indications. It uses a proprietary integrated technology platform to design antibodies that are more potent and resistant to viral evolution.
- Who founded Invivyd?
- Invivyd was founded by Marc Elia.
- Who are Invivyd's investors?
- Invivyd's investors include Bain Capital Life Sciences, Foresite Capital, MRL Ventures Fund, Premji Invest, Mithril Capital Management.